Lung cancer
CA240-0029
A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion.
Trial overview
Clinical Area
Medical Oncology
Disease
Lung
Disease site
Lung & bronchus
Study Phase
II
Trial Identifiers
Registration number: NCT07063745
Principal Investigator(s)
··
··